Patents Examined by Savitha Rao
  • Patent number: 10202385
    Abstract: The present invention relates to: —use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of cancer; —combinations of a) said compound and b) one or more further active agents; —a pharmaceutical composition comprising said compound as a sole active agent for the treatment of breast cancer; —a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; —use of biomarkers involved in the modification of Bel expression, HER family expression and/or activation, PIK3CA signaling and/or loss of PTEN for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity an
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: February 12, 2019
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ningshu Liu, Claudia Schneider
  • Patent number: 9951078
    Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as ERK (MAPK). Also provided are methods of using such compounds or compositions, and methods of using these compositions to modulate the activities of one or more of these kinases, especially for therapeutic applications such as the treatment disorders such as cancer.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: April 24, 2018
    Assignee: KURA ONCOLOGY, INC.
    Inventors: Liansheng Li, Tao Wu, Jun Feng, Pingda Ren, Yi Liu
  • Patent number: 9908843
    Abstract: The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof: (I) wherein: n is 0 or 1; R1 is selected from H, alkyl and aralkyl, wherein said alkyl and aralkyl groups may be optionally substituted by one or more OH groups; X is a group selected from —C?C—(CH2)p—; —C(R5)?C(R6)—(CH2)q—; and —C(R5)(R6)C(R7)(R8)—(CH2)r-; where each of R5, R6, R7 and R8 is independently H or alkyl, and each of p, q and r is independently 1, 2, 3, 4 or 5; Y is a group selected from: CN; COOR2; CONR3R4; SO2NR9R10; NR12COR13; NR14SO2R15; and a heterocyclic group selected from oxadiazolyl, thiazolyl, iso-thiazolyl, oxazolyl, iso-oxazolyl, pyrazolyl and imidazolyl; where each of R2, R3 and R4 is independently H or alkyl; or R3 and R4 are linked, together with the nitrogen to which they are attached, to form a 5 or 6-membered heterocycloalkyl or heterocycloalkenyl group, said heterocycloalkyl or heterocycloalkenyl group optionally containing one or more further groups selected from O, N, CO an
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: March 6, 2018
    Assignee: CANBEX THERAPEUTICS LIMITED
    Inventor: David Selwood
  • Patent number: 9896464
    Abstract: Compounds having the following formula (E): Formula E or a pharmaceutically acceptable salt thereof, wherein R, R?, R?, X and n are as defined herein are provided. Methods comprising use of such compounds for the treatment of neurologic disorders, such as pantothenate kinase-associated neurodegeneration, and pharmaceutical compositions containing such compounds, and their use in treatment of neurologic disorders are also provided.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: February 20, 2018
    Assignee: Retrophin, Inc.
    Inventors: Andrew Vaino, Marek Biestek, Martin Shkreli
  • Patent number: 9896731
    Abstract: Methods and formulations for treating onocological disorders in humans using Coenzyme Q10 are described.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: February 20, 2018
    Assignee: Berg LLC
    Inventors: Niven Rajin Narain, John Patrick McCook
  • Patent number: 9895337
    Abstract: The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of STAT-3 known to be a therapeutic target for rheumatoid arthritis. As the monoacetyldiacylglycerol is an effective therapeutic agent without toxicity, the monoacetyldiacylglycerol can overcome the side effects of the medicines currently used in the treatment of rheumatoid arthritis. Thus, the monoacetyldiacylglycerol can be used for preventing, treating or improving rheumatoid arthritis.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: February 20, 2018
    Assignees: Enzychem Lifesciences Corporation, Korea Research Institute of Bioscience and Biotechnology
    Inventors: Jae Wha Kim, Sei Ryang Oh, Kyung Seop Ahn, Ho Bum Kang, Beom Su Park, Tae Suk Lee, Jong Koo Kang, Young Sik Jung, Ki-Young Sohn
  • Patent number: 9889126
    Abstract: Described herein is a method of using a topical, pharmaceutical composition, particularly a dermatological composition, comprising naratriptan to treat rosacea and in particular erythematotelangiectatic rosacea.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: February 13, 2018
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Michel Rivier, Isabelle Carlavan, Jerome Aubert
  • Patent number: 9879014
    Abstract: A compound and a pharmaceutical composition for disease associated with an abnormal splice variant, use of the compound and the pharmaceutical composition, or a screening method of the compound and the pharmaceutical composition are provided. One or more embodiments disclose a compound expressed by the following formula (I) or (I?) or prodrugs or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: January 30, 2018
    Assignee: KYOTO UNIVERSITY
    Inventors: Masatoshi Hagiwara, Suguru Yoshida, Takamitsu Hosoya
  • Patent number: 9877956
    Abstract: Inhibitors of retroviral propagation, methods of treatment and prevention of retroviral infections using the inhibitors, and pharmaceutical compositions including the inhibitors, are disclosed.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: January 30, 2018
    Assignee: TRANA DISCOVERY, INC.
    Inventors: Richard H. Guenther, Daniel Sternbach, Steven E. Peterson
  • Patent number: 9873683
    Abstract: The present invention relates to a compound represented by the following general formula (II), wherein, in the formula, R1a to R6a represent hydrogen atom, an alkyl group having 1 to 8 carbon atoms, and the like, Xa represents C or N, Ya represents N or C(?O), provided that when Xa is C, Ya represents N, and when Xa is N, Ya represents C(?O), the double line consisting of the solid line and the broken line represents a single bond or double bond, Aa represents benzene ring, pyridine ring, and the like, Da represents tetrazole ring, imidazole ring, and the like, Ea represents —(CR9aR10a)p-Ta-, and Ga represents benzene ring, pyridine ring, and the like, which has a P2X4 receptor antagonistic activity.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: January 23, 2018
    Assignees: NIPPON CHEMIPHAR CO., LTD, KYUSHU UNIVERSITY
    Inventors: Shogo Sakuma, Kunio Kobayashi, Masatoshi Ushioda, Daisuke Saito, Toshiyasu Imai, Kazuhide Inoue
  • Patent number: 9867375
    Abstract: The present invention provides methods comprising applying to a crop of soybean plants, the locus thereof, or propagation material thereof, a compound of formula (I) wherein —B1—B2—B3— is —C?N—O—, —C?N—CH2—, —N—CH2—CH2—, or —C?C—O—; R1 is trifluoromethyl, difluoromethyl or chlorodifluoromethyl; R2 is group (X) wherein X2 is C—X6 or nitrogen; X1, X3 and X6 are independently hydrogen, halogen or trihalomethyl, wherein at least one of X1, X3 and X6 is not hydrogen; A is selected from group (A1) to (A4) and Y1, Y2, Y3, R5 and R8 are as defined in claim 1. The methods are preferably for the control of stinkbugs, in particular Euschistus.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: January 16, 2018
    Assignee: Syngenta Participations AG
    Inventors: Myriem El Qacemi, Jerome Yves Cassayre
  • Patent number: 9867809
    Abstract: A method of forming a granule having an internal three-dimensional framework of channels to control and sustain the release of an active ingredient for enteric delivery of the active ingredient in an animal fed the granule. In the composition of the granules hydrogenated vegetable oil, HVO for example, is combined with a modifier to create a granule with channels through which the active ingredient is released. The active ingredients, including but not limited to metal salts of butyric acid, can be released in the lower gut of the animal where it will best benefit the animal. By adjusting the amount of the modifier, the release rate of the active can be adjusted to suit the passage rate of the species of animal being fed.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: January 16, 2018
    Assignee: KEMIN INDUSTRIES, INC.
    Inventors: Mitchell Poss, Thoai Pham, David Sanders, Jon Rubach, Shulin Feng
  • Patent number: 9867828
    Abstract: Embodiments of the present invention provide dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Within certain embodiments, the present invention provides a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: January 16, 2018
    Assignee: Aminopterin LLC
    Inventor: John A. Zebala
  • Patent number: 9867789
    Abstract: The use of a non-steroidal anti-inflammatory drug for the treatment of nonproductive cough caused by viruses or bacteria and a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive in a formulation to treat coughs.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: January 16, 2018
    Assignee: BAYER CONSUMER CARE AG
    Inventors: Marianne Petersen-Braun, Chirin Yekrangi-Hartmann, Uwe Gessner, Michael Völker
  • Patent number: 9861597
    Abstract: The present invention is drawn to the treatment of neonatal patients exhibiting convulsion comprising administering a composition comprising a gluconate complex, wherein said gluconate complex lacks a divalent cation such as sodium gluconate.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: January 9, 2018
    Assignee: Penn State Research Foundation
    Inventors: Gong Chen, Zheng Wu
  • Patent number: 9851354
    Abstract: The present invention provides methods of alleviating a sign or a symptom of Fragile X Syndrome and relates disorders such as autism spectrum disorders.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: December 26, 2017
    Assignee: Alcobra Ltd.
    Inventors: Yaron Daniely, Dalia Megiddo
  • Patent number: 9849108
    Abstract: A composition is provided that includes a cannabinoid capable of inducing a pharmacological effect, an ester, a condensation aerosol, and a carrier liquid solution of food grade materials. The cannabinoid may include a bio-active ingredient receivable by a cannabinoid receptor and/or an acetylcholine receptor. The pharmacological effect may be produced by reception of tetrahydrocannabinol, cannabidiol, or mixtures thereof. The composition may also include ethanol, flavoring agents, and aromatherapy agents. The composition is deliverable to a user via vaporization. A method is provided for creating a pharmacological effect using the composition.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: December 26, 2017
    Inventor: Stephen C. Perry
  • Patent number: 9844543
    Abstract: The present invention provides a method of treating or preventing hyperlipidemia in a subject in need thereof. Such method includes, specifically, administrating to the subject a therapeutically effective amount of a caffeamide derivative. The present invention also provides a pharmaceutical composition containing, primarily, the caffeamide derivative. The method and pharmaceutical composition of the present invention can effectively and significantly lower the high-fat diet-induced body weight gain and absolute visceral fat weight as well as the concentration of triglycerides and free fatty acids in blood, and levels of total lipid and triacylglycerol in liver tissue. In addition, the caffeamide of the present invention also reduces size of adipocyte, hepatocellular ballooning phenomenon, and liver steatosis.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: December 19, 2017
    Inventor: Chun-Ching Shih
  • Patent number: 9839620
    Abstract: An anise flavored liquid medication. The liquid medication contains phenylephrine and an anethole analog that is substantially free of aldehyde groups. In one example, the anethole analog can be 1-methoxy-4-n-propylbenzene.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: December 12, 2017
    Assignee: The Procter & Gamble Company
    Inventors: Allyn Michael Kaufmann, James Carl Grimm, Chelsay Lynn Brewster, Thomas Edward Huetter
  • Patent number: 9840497
    Abstract: The present invention relates to a compound represented by the following general formula (II), wherein, in the formula, R1a to R6a represent hydrogen atom, an alkyl group having 1 to 8 carbon atoms, and the like, Xa represents C or N, Ya represents N or C(?O), provided that when Xa is C, Ya represents N, and when Xa is N, Ya represents C(?O), the double line consisting of the solid line and the broken line represents a single bond or double bond, Aa represents benzene ring, pyridine ring, and the like, Da represents tetrazole ring, imidazole ring, and the like, Ea represents —(CR9aR10a)p-Ta-, and Ga represents benzene ring, pyridine ring, and the like, which has a P2X4 receptor antagonistic activity.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: December 12, 2017
    Assignees: NIPPON CHEMIPHAR CO., LTD, KYUSHU UNIVERSITY
    Inventors: Shogo Sakuma, Kunio Kobayashi, Masatoshi Ushioda, Daisuke Saito, Toshiyasu Imai, Kazuhide Inoue